Fresenius Kabi recalls 4 lots of benztropine mesylate injection
Fresenius Kabi USA on June 30, 2013 issued a voluntary, user-level product recall of 4 lots of benztropine mesylate injection, USP, 2 mg/2 mL (1 mg/mL) in 2 mL single-dose vials, due to the possibility of glass particles in the vials.
Fresenius Kabi USA on June 30, 2013 issued a voluntary, user-level product recall of 4 lots of benztropine mesylate injection, USP, 2 mg/2 mL (1 mg/mL) in 2 mL single-dose vials, due to the possibility of glass particles in the vials.
The specific lots recalled are lot 030712, expiration 03/2014; lot 071212, expiration 07/2014; lot 090512, expiration 09/2014; and lot 970102, expiration 11/2014.
The drug is used as an adjunct in the therapy of all forms of Parkinsonism. It is useful also in the control of extrapyramidal disorders due to neuroleptic drugs, except tardive dyskinesia.
To date, no adverse events, patient reactions, or customer complaints have been reported, and Fresenius Kabi has discontinued distribution of benztropine mesylate while it investigates the cause.
Customers who received the recalled vials are being notified and instructed to return any unused product to Fresenius Kabi USA. Any adverse reactions should be reported to the FDA’s MedWatch Adverse Event Reporting program.
To get weekly news from the voice of the pharmacist, subscribe to the Drug Topics Community Pharmacists' Report or the Drug Topics Hospital Pharmacists' Report.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
